We evaluated the incidence of perioperative hyperkalaemia in end-stage renal disease (ESRD) patients undergoing parathyroidectomy and investigated possible contributors to this phenomenon. This was a retrospective cohort study looking at patients who had undergone parathyroidectomy for chronic kidney disease-associated mineral bone disease (CKD-MBD) at The Alfred Hospital, Melbourne, since 2001. Baseline demographics including age, gender, aetiology of renal failure and mode of renal replacement therapy as well as anaesthetic technique and duration of surgery were studied as possible contributors.
Introduction
Progressive deterioration of kidney function toward end-stage renal disease (ESRD) is associated with an acquired disturbance of calcium and phosphorus handling and the parathyroid axis [1] [2] . Secondary and later tertiary hyperparathyroidism follows an established trajectory in chronic renal disease 3 with significant morbidity and mortality implications 4 . More recently this phenomenon has been renamed chronic kidney disease-associated mineral bone disease (CKD-MBD) 5 . Medical management of these complex disturbances in mineral metabolism has traditionally included dietary phosphate binders and activated vitamin D supplementation 6, 7 . In the last decade, cinacalcet has been widely used as an allosteric activator of parathyroid calciumsensing receptors, targeted to reduce serum parathormone levels 8 . The rate of surgical parathyroidectomy fell dramatically with the introduction of this agent [9] [10] [11] . However, firm outcome data supporting the role of cinacalcet was not well established.
Following the publication of the EVOLVE (Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events) trial 12 , a large multinational, prospective, randomised, controlled double-blind trial of cinacalcet versus placebo in haemodialysis patients which failed to reach primary endpoints, cinacalcet was controversially withdrawn from the Australian Pharmaceutical Benefits Scheme subsidised list in August 2015. Consequently, the rate of operative parathyroidectomy in ESRD patients in our centre has increased from occasional surgery to now over one-third of our centre's parathyroidectomy case-mix. A small study recently suggested a superiority of subtotal parathyroidectomy over cinacalcet for the management of tertiary hyperparathyroidism in renal transplant patients, with improved correction of hypercalcaemia 13 .
Whilst the hungry-bone syndrome is a welldescribed phenomenon following subtotal and total parathyroidectomy resulting in severe and sustained hypocalcaemia, significant variation in serum potassium may also be seen in this cohort. Potentially life-threatening hyperkalaemia is an important, but often under-recognised, complication of surgery in this population. One published prospective study reported a 58% incidence of potassium rises over 0.5 mmol/l 14 , whilst a retrospective case series 15 observed hyperkalaemia in 25%. Risk factors have not been clearly defined in the literature, and warrant further investigation.
This retrospective cohort study was instigated following the development of life-threatening hyperkalaemia in a 36-year-old male undergoing subtotal parathyroidectomy for CKD-MBD. His intraoperative potassium was measured due to the appearance of dynamic T wave tenting on his electrocardiogram, and was found to be 8.1 mmol/l, a rise of 2.8 mmol/l from his preoperative baseline of 5.3 mmol/l.
The aims of this study were to investigate the incidence of perioperative hyperkalaemia in ESRD patients undergoing parathyroidectomy in our institution, and identify possible risk factors for this phenomenon.
Methods
We reviewed the charts of all ESRD patients who had undergone subtotal or total parathyroidectomy for CKD-MBD at Alfred Health since 2001. Patients who had ESRD defined by an estimated glomular filtration rate less than 15 ml/min/1.73 m 2 and on renal replacement therapy via peritoneal dialysis or haemodialysis were included. Patients with functioning renal transplants at the time of surgery were excluded.
Baseline demographics were analysed including age, gender, aetiology of renal failure and mode of renal replacement therapy. Duration of surgery was measured as time between incision and wound closure. The most recent preoperative potassium result was considered the baseline, usually taken following dialysis on the day before surgery. Perioperative potassium results were from samples taken intraoperatively where available, or the first postoperative plasma potassium. Preoperative serum parathyroid hormone and alkaline phosphatase (ALP) levels, in addition to nadir corrected calcium up to one week postoperatively, were used as a marker of effective CKD-MBD management.
Alterations in serum potassium were considered across relative and absolute levels of significance; (i) a periprocedural rise in serum potassium ≥0.5 mmol/l, (ii) hyperkalaemia, defined as a serum potassium ≥5.5 mmol/l 16 , (iii) significant hyperkalaemia, defined as an absolute serum level ≥6 mmol/l and (iv) life-threatening hyperkalaemia, defined as an absolute serum level ≥7 mmol/l.
Results
Twenty-two patients met the inclusion criteria ( Table 1) . All patients were American Society of Anesthesiologists classification 3 at time of surgery. The most common form of renal replacement therapy was haemodialysis, accounting for nearly two-thirds of the cohort. Arterial lines were sited in 12 cases. Suxamethonium was used in one case only and compound sodium lactate and 0.9% normal saline were used as intraoperative crystalloids in 12 (54%) and nine (46%) of procedures, respectively.
There was a rise in serum potassium from a median (interquartile range, IQR) baseline of 4.65 (4.0 to 5.2) mmol/l to 4.95 (4.4 to 5.8) mmol/l during the perioperative period ( Figure 1 ). Thirteen patients (59%) had a measured potassium rise of 0.5 mmol/l or greater. Of these, seven had potassium rises of 0.5 to 1 mmol/l, three had potassium rises of 1 to 2 mmol/l, and three had potassium increases greater than 2 mmol/l.
There were six cases of absolute perioperative hyperkalaemia, with an incidence of 27.3% in this series. Three of the six were classed as severe hyperkalaemia, and three were considered as life-threatening. There was no difference in patient age, preoperative parathyroid hormone and ALP or nadir corrected calcium levels between the normokalaemic or hyperkalaemic groups. However, the median duration of surgery was longer in the hyperkalaemic patients (167 minutes versus 125 minutes). Where arterial lines had been placed and intraoperative sampling undertaken there was no change in acid-base status associated with serum potassium change.
Discussion
In this series we found a 27.3% rate of perioperative hyperkalaemia in patients with ESRD undergoing parathyroidectomy, similar to that reported previously 15 . There were no significant demographic predictors of hyperkalaemia, but hyperkalaemic patients had longer surgical times.
As a predominantly intracellular ion, potassium is disproportionately distributed such that approximately only 3% of total body stores are measurable in the extracellular fluid compartment 17 . In the setting of ESRD, the homeostatic matching of renal excretion to dietary potassium intake is disrupted and patients rely upon dialysis as a surrogate provider of solute and electrolyte clearance. More dynamic maintenance of serum potassium levels relies upon flux from the extracellular to intracellular compartment, largely under the control of energy dependent sodium-potassium transmembrane channels affected by multiple metabolic inputs, including acid-base and endocrine 18 . Persistent elevations of serum potassium are often tolerated in the chronic kidney disease cohort 19 , but still independently predict a significant increase in overall mortality risk 20 . The exact causes of the observed potassium changes are unclear, though likely to be multifactorial, including catabolism, tissue trauma, medication-related causes and transmembrane flux. Two theoretically possible anaesthetic practices that might directly predispose to hyperkalaemia are the use of depolarising neuromuscular blockers and the delivery of potassium-containing intravenous fluids. In this series, the one patient who received suxamethonium had no potassium rise, and only normal saline or compound sodium lactate was used as intravenous fluid therapy. There was no evidence that acidaemia was directly responsible for the observed variation; however, in the context of such rapid fluctuation in measured serum potassium level, transmembrane potassium shift is an attractive potential unifying mechanism. In the context of longer operative time and tendency toward male predominance observed by others 14 , we speculate that these factors might contribute to substantive efflux of potassium from the intracellular compartment.
The risk of significant cardiovascular sequelae from hyperkalaemia is elevated in this patient population where there is significant possibility of rapid concomitant hypocalcaemia once the parathyroid glands are excised 21 . These data suggest a strong indication for intraoperative electrolyte monitoring, however the frequency and route of blood sampling in this patient population is both controversial and dependent on local practice. In renal patients, arterial line insertion poses a potential threat to future sites of arteriovenous fistula formation for haemodialysis and would not appear justified for electrolyte monitoring alone in the absence of an alternative indication.
At our centre, central lines are routinely used for postoperative intravenous calcium supplementation to minimise the risks posed by extravasation of calcium from peripheral cannulae. Previously, central lines were sited by the surgeon, however this study has resulted in a change in perioperative practice. We recommend that central lines are sited by the anaesthetist prior to incision, facilitating blood sampling intraoperatively, and elimination of arterial lines unless otherwise indicated.
There are several limitations to our study. The number of patients is small, which limits the power of the study's conclusions. However, this reflects that, in the decade up to 2015, medical management was providing effective control of secondary hyperparathyroidism in patients with ESRD. As a retrospective analysis, neither the timing of patients' baseline plasma potassium nor of the perioperative measurements was standardised. Therefore, peak plasma potassium concentrations may have been missed in patients who only had bloods taken postoperatively. Whilst this limits our ability to comment on peak potassium rises, it suggests that this study might be under-reporting the true incidence of perioperative hyperkalaemia in this group of patients. Similarly, serial monitoring of temperature, acidbase, endocrine measures and creatine kinase may provide more robust mechanistic insights.
This study highlights the need to raise awareness of this phenomenon. Given the potential gravity of these observations, there is a strong indication for active electrolyte surveillance. As surgical caseload increases following the withdrawal of cinacalcet in Australia, there will be scope to prospectively investigate the patterns of perioperative electrolyte change and pre-emptively initiate discussion with nephrologists regarding definitive electrolyte removal through emergent dialysis. 
Conclusion
We report a significant incidence of perioperative hyperkalaemia in ESRD patients undergoing parathyroidectomy for CKD-MBD. The degree of perioperative potassium rise is atypical and may be lifethreatening. Anaesthetists, endocrine surgeons and nephrologists must be alert to the frequency and danger of potential morbidity and mortality from this phenomenon, and a multidisciplinary approach is required to ensure safe perioperative practice. Whilst the physiologic mechanisms are not completely clear, identification of risk, liaison with nephrologists around the timing of perioperative renal replacement therapy and timely monitoring throughout the perioperative course should form the basis of harmminimisation strategies.
